Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10805
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPatterson, Scott J-
dc.contributor.authorAngus, Peter W-
dc.date.accessioned2015-05-16T00:22:29Z
dc.date.available2015-05-16T00:22:29Z
dc.date.issued2009-06-01-
dc.identifier.citationCurrent Opinion in Organ Transplantation; 14(3): 225-30en_US
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10805en
dc.description.abstractThe established gold standard for prophylaxis against hepatitis B virus (HBV) recurrence post-liver transplant is combination hepatitis B immune globulin (HBIG) and lamivudine. This therapy reduces the risk of recurrence to less than 5% at 5 years; however, the cost of HBIG has led to the investigation of alternatives. This paper reviews the HBIG-sparing alternatives achieved with lamivudine and the prospects for the newer anti-HBV agents in post-liver transplant prophylaxis.When used with lamivudine as part of combination prophylaxis, low-dose intramuscular HBIG is equivalent to high-dose intravenous HBIG. There is recent evidence that in patients receiving HBIG/lamivudine, HBIG can be replaced with adefovir dipivoxil at 6-12 months post-liver transplant without precipitating recurrence. Furthermore, a recent study showed that primary prophylaxis with combination adefovir/lamivudine therapy without the use of long-term HBIG was effective and well tolerated as primary prophylaxis.Although there are few studies of potent newer anti-HBV agents such as entecavir or tenofovir being used as HBV prophylaxis, the properties of these drugs suggest that they should replace lamivudine within HBV prophylaxis regimes.en_US
dc.language.isoenen
dc.subject.otherAdenine.administration & dosage.analogs & derivativesen
dc.subject.otherAdministration, Oralen
dc.subject.otherAntiviral Agents.administration & dosage.adverse effectsen
dc.subject.otherDrug Administration Scheduleen
dc.subject.otherDrug Therapy, Combinationen
dc.subject.otherGraft Survival.drug effectsen
dc.subject.otherGuanine.administration & dosage.analogs & derivativesen
dc.subject.otherHepatitis B.prevention & control.surgeryen
dc.subject.otherHumansen
dc.subject.otherImmunoglobulins.administration & dosageen
dc.subject.otherInjections, Intramuscularen
dc.subject.otherLamivudine.administration & dosageen
dc.subject.otherLiver Transplantation.adverse effectsen
dc.subject.otherNucleosides.administration & dosage.adverse effectsen
dc.subject.otherNucleotides.administration & dosage.adverse effectsen
dc.subject.otherOrganophosphonates.administration & dosageen
dc.subject.otherSecondary Preventionen
dc.subject.otherTreatment Outcomeen
dc.titlePost-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleCurrent Opinion in Organ Transplantationen_US
dc.identifier.affiliationVictorian Liver Transplant Uniten_US
dc.identifier.doi10.1097/MOT.0b013e32832b1f32en_US
dc.description.pages225-30en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/19373086en
dc.type.contentTexten_US
dc.type.austinJournal Articleen
local.name.researcherAngus, Peter W
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptGastroenterology and Hepatology-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.